RCUS

15.6650.73%
YK

Yasunori Kaneko

Lead Independent Director

Dr. Yasunori Kaneko, M.D., serves as a Managing Director of Skyline Ventures, Skyline Ventures IV, L.P. and Skyline Ventures III, L.P. Dr. Kaneko has been Director at Arcus Biosciences, Inc., since May 2015 and also Lead Independent Director. Dr. Kaneko joined Skyline Ventures in 1999. He has been actively involved in managing and financing United States life sciences companies since 1981. Previously, in 1992, he was recruited to be the original business executive at Tularik Inc., where at various times He served as the Chief Financial Officer and Vice President of Business Development until its public offering in 1999. He was a Managing Director at Skyline Venture Partners, L.P., a venture capital firm, from January 1999 to January 2019. He served as Senior Vice President at Isis Pharmaceuticals, Inc. and its Chief Financial Officer from 1991 to 1992. He served as a Senior Vice President and Chief Financial Officer of Ionis Pharmaceuticals, Inc., a pharmaceutical company, which went public in May 1991 during his tenure from 1991 to 1992. From 1987 to 1991, he served as the Head of Corporate Finance in the Investment Banking Division at Paribas Capital Markets Ltd. in Tokyo from 1987 to 1991, where he helped finance Japanese government agencies, municipalities and corporations in the Euro market. He also helped numerous life sciences companies raise capital. He was a Project Manager for the launch of Protropin at Genentech, Inc., from 1981 to 1987. He began his career at Genentech, where he also spearheaded its business development activities for the first several years. He had been an Independent Director of Nippon Paint Holdings Co., Ltd. since March 28, 2018 till March 2020. He has been an Outside Director at TolerRx Inc. since October 2001. He served as an Outside Director at MIRACA Holdings Inc since June 2006 until June 24, 2016. He serves as Director at ThiosPharmaceuticals, Inc. He served as a Director at LeukoSite, Inc., since February 1998 until 1999, Renovis Inc. since July 2000 until June 5, 2006. and Tolerx, Inc., since September 2001. He served as Director of Zyomyx, Inc., Guava Technologies, Inc., KAI Pharmaceuticals, Inc. and Marquis Tech Holdings, Inc. He is a member of the Stanford Interdisciplinary Life Sciences Council and serves on the board of Provigate Incorporated. Dr. Kaneko received an M.B.A. from Stanford Graduate School of Business, a Medical degree from Keio University School of Medicine and an undergraduate degree from Keio University in Tokyo.

Positions